Seeking to explore new markets! Novo Nordisk claims its weight loss drug is safe and effective for children under 12 years old. According to a new study funded by Novo Nordisk, one of the company's weight loss drugs is safe and effective for 6-year-old children, paving the way for Liraglutide to become the first obesity treatment drug for children in this age group. The experimental results showed that children aged 6 to 12 who used the Novo Nordisk Weight Loss Injection Pen (Saxenda) for just over a year had a 7.4% decrease in body mass index compared to those who received a placebo.